< Key Hightlight >

MARKET OUTLOOK

Triton’s research report on the Asia-Pacific infertility testing and treatment market predicts the market to grow at a CAGR of 10.42% through the estimated years 2021-2028. South Korea, India, China, Japan, Australia & New Zealand, ASEAN countries, and Rest of Asia-Pacific outline the market in this region.

India is estimated to witness the fastest growth rate in the infertility testing and treatment market in the region. The growth in stress levels, irregular sleep patterns, and sedentary lifestyles are key factors causing infertility among the country’s populations. This has compelled several couples to opt for artificial ways of conceiving. Additionally, external factors, such as pollution, impact semen production. Furthermore, the growing prevalence of diabetes and obesity has increased the chances of infertility among people. Above all, the low cost of IVF compared to other nations opens new opportunities for fertility tourism. Hence, these factors are opening new avenues for the Indian infertility testing and treatment market across India. 

South Korea, for instance, is emerging as a global leader in the healthcare market, offering high quality services at relatively affordable costs. In the field of infertility treatment, the country is leading, along with Japan. The studied market’s growth is mainly driven by the rise in patient visits for fertility treatments. In addition, the supportive government policies are adding to the market’s overall development. Infertility treatment, especially IVF, has gained significant traction across the country, generating opportunities for fertility clinics. Therefore, as stated above, all these factors are estimated to widen the infertility testing and treatment market’s growth in South Korea. 

COMPETITIVE OUTLOOK 

The key companies profiled in the infertility testing and treatment market are Genea Ltd, Labotect GmbH, Cook Medical Inc, Endo International Plc, Bangkok IVF Center, Cooper Surgical, and Progyny.